Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.


In a pandemic, the development of an effective influenza vaccine is the most important subject from the view of public health. This study was performed to evaluate the immunogenicity and safety of inactivated, monovalent H1N1 2009 vaccine (Green Cross Corporation, Yongin, Korea) among healthy adults aged 19-64 years (Group 1) and the elderly aged ≥ 65 years… (More)
DOI: 10.1016/j.vaccine.2010.10.060


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics